Sarcoidosis and Anti-TNF: a Paradoxial Class Effect? Analysis of the French Pharmacovigilance System Database and Literature Review

被引：10

作者：

Javot, Lucie ^{[1
]}

Tala, Stephane ^{[1
]}

Scala-Bertola, Julien ^{[1
]}

Massy, Nathalie ^{[2
]}

Trenque, Thierry ^{[3
]}

Baldin, Bernadette ^{[4
]}

Andrejak, Michel ^{[5
]}

Gillet, Pierre ^{[1
]}

Petitpain, Nadine ^{[1
]}

机构：

[1] Hop Cent, Ctr Reg Pharmacovigilance, CHU, F-54035 Nancy, France

[2] Hop Charles Nicolle, Ctr Reg Pharmacovigilance, Inst Biol Clin, Rouen, France

[3] Hop Robert Debre, Ctr Reg Pharmacovigilance, Reims, France

[4] Hop Cimiez, Ctr Reg Pharmacovigilance, F-06003 Nice, France

[5] CHU Hop Sud, Ctr Reg Pharmacovigilance, Serv Pharmacol, Amiens, France

来源：

THERAPIE | 2011年 / 66卷 / 02期

关键词：

sarcoidosis; granulomatosis; TNF blockade; biotherapy; RHEUMATOID-ARTHRITIS; PULMONARY SARCOIDOSIS; ANKYLOSING-SPONDYLITIS; ALPHA TREATMENT; ETANERCEPT; PATIENT; INFLIXIMAB;

D O I：

10.2515/therapie/2011014

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sarcoidosis and Anti-TNF: a Paradoxial Class Effect? Analysis of the French Pharmacovigilance System Database and Literature Review. Objectives. To identify and characterize the observations of sarcoidosis occurring during anti-TNF blockade collected in the French Pharmacovigilance system database and reported in the literature. Results. Seven cases were reported in the French Pharmacovigilance system database and 39 cases (37 original) have been reported internationally. Monoclonal antibodies (infliximab and adalimumab) and fusion protein (etanercept) are equally involved. Sarcoidosis have been confirmed histologically and occurred predominantly in the rheumatoid arthritis (22) and spondylarthropathy (16). Conclusion. The lack of protopathic bias suggests that these paradoxical sarcoidosis occurring during treatment with anti-TNF are a class-effect, as with psoriasis, uveitis, and IBD reported under similar conditions. Their pathogenesis remains unclear.

引用

页码：149 / 154

页数：6

共 39 条

[1]

Al-Shami AA, 2008, RHEUMATOLOGY, V47, pII161

[2] Off-label dermatologic uses of anti-TNF-a therapies [J].

Alexis, Andrew F. ;

Strober, Bruce E. .

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2005, 9 (06) :296-302

[3]

Almodóvar R, 2007, CLIN EXP RHEUMATOL, V25, P99

[4] Granulomatous tattoo reaction in a patient treated with etanercept [J].

Bachmeyer, C. ;

Blum, L. ;

Petitjean, B. ;

Kemiche, F. ;

Pertuiset, E. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2007, 21 (04) :550-552

[5]

Baughman RP, 2008, SARCOIDOSIS VASC DIF, V25, P76

[6] Treatment of therapy-resistant sarcoidosis with adalimumab [J].

Callejas-Rubio, Jose Luis ;

Ortego-Centeno, Norberto ;

Lopez-Perez, Lourdes ;

Benticuaga, Maria Nicolas .

CLINICAL RHEUMATOLOGY, 2006, 25 (04) :596-597

[7] Epidemiology of sarcoidosis and its genetic and environmental risk factors [J].

Chapelon-Abric, C .

REVUE DE MEDECINE INTERNE, 2004, 25 (07) :494-500

[8] Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab [J].

Cruz, Boris A. ;

Reis, Dorothy D. ;

Araujo, Celia Aparecida A. .

RHEUMATOLOGY INTERNATIONAL, 2007, 27 (12) :1181-1183

[9] Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases [J].

Daien, Claire Immediato ;

Monnier, Agnes ;

Claudepierre, Pascal ;

Constantin, Arnaud ;

Eschard, Jean-Paul ;

Houvenagel, Eric ;

Samimi, Mahtab ;

Pavy, Stephan ;

Pertuiset, Edouard ;

Toussirot, Eric ;

Combe, Bernard ;

Morel, Jacques .

RHEUMATOLOGY, 2009, 48 (08) :883-886

[10] Cutaneous Sarcoidosis Occurring during Anti-TNF-Alpha Treatment: Report of Two Cases [J].

Dhaille, F. ;

Viseux, V. ;

Caudron, A. ;

Dadban, A. ;

Tribout, C. ;

Boumier, P. ;

Clabaut, A. ;

Lok, C. .

DERMATOLOGY, 2010, 220 (03) :234-237

← 1 2 3 4 →